The global market for cancer vaccines should grow from $8.1 billion in 2021 to $11.7 billion by 2026 with a compound annual growth rate (CAGR) of 7.6% for the period of 2021-2026.
North American cancer vaccines market should grow from $3.6 billion in 2021 to $5.3 billion by 2026 with a compound annual growth rate (CAGR) of 7.8% for the period of 2021-2026.
The European cancer vaccines market should grow from $2.1 billion in 2021 to $2.9 billion by 2026 with a compound annual growth rate (CAGR) of 7.0% for the period of 2021-2026.
Report Scope:
The scope of this study involves the global market of cancer vaccines. The report covers the entire market of cancer vaccines, which includes two main areas of application, prophylactic vaccines and therapeutic vaccines. Discussion of human papillomavirus vaccines and hepatitis B vaccines that indirectly act against cancer is also included in the report.
Based on application, the market covers various cancer types such as prostate, liver, cervical, lung and bladder. Both marketing and research and development (R&D) perspectives are discussed in the report.
By geography, the market has been divided into four regions: North America, Europe, Asia-Pacific and the Rest of the World. Detailed analyses of major countries such as the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China and India are covered in regional segments. For market estimates, data have been provided for the year 2020 as the base year, with forecasts for 2021 through 2026.
Patent analysis, clinical trials, innovative research and opportunities of the newest trends within the cancer vaccine market and comprehensive profiles of companies that lead the cancer vaccine industry are also discussed.
The Report Includes:
- 20 data tables and 23 additional tables
- An overview of the global markets and technologies for cancer vaccines
- Estimation of the market size and analyses of global market trends, with data from 2019, 2020, estimates for 2021 with projections of compound annual growth rates (CAGRs) through 2026
- Detailed description of history, management, and causes of cancer including genetic factors, lifestyle factors and environmental factors, and information on types of cancer-causing genes
- Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast, and an overview of current and future dynamics of the global market for various cancer vaccines
- Discussion on present and future strategies within the cancer vaccines market, and comparative assessment of prophylactic vaccines and therapeutic vaccines
- Coverage of approved cancer vaccines, recalls, fast track designations and orphan drug designation and analysis of pipeline products and patents
- Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies
- Comprehensive company profiles of the leading players of the industry, including Amgen Inc., Dendreon Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co. Inc. and Vaccinogen Inc.
Table of Contents
Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Information Sources
- Methodology
- Intended Audience
- Geographic Breakdown
- Analyst's Credentials
- Custom Research
- What's New in This Report
- Related Reports
Chapter 2 Summary and Highlights
- Market Size and Evolution
Chapter 3 Market Overview
- Definition
- History of Cancer and Its Management
- Causes of Cancer
- Genetic Factors
- Lifestyle Factors
- Environmental Factors
- Types of Cancer-Causing Genes
- Immune System and Cancer
- Classification of Cancer
- Cancer Prevention
- Types of Cancer Treatment
- Surgery
- Radiation Therapy
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- Hormone Therapy
- Cancer Vaccines
- Liver Cancer
- Prostate Cancer
- Cervical Cancer
- Cancer Vaccines Platform
- Tumor-Cell Vaccines
- Cancer Stem Cell Vaccines
- Peptide/Protein Vaccines
Chapter 4 Impact of COVID-19 on the Market
- Overview
- Current Outlook
- COVID-19 Impact on Cancer Care
Chapter 5 Regulatory Aspects
- Overview
- Regulatory History of Approved Cancer Vaccines
- Recalls
- Orphan Drug Designation
- Fast-Track Designations
Chapter 6 Market Breakdown by Type
- Overview
- Market Overview
- Market Revenue
- Therapeutic Vaccines
- Market Overview
- Market Revenue
- Prophylactic Vaccines
- Market Overview
- Market Revenue
Chapter 7 Market Breakdown by Application
- Overview
- Cancer Vaccines Application in Various Cancers
- Market Revenues
- Prostate Cancer
- Market Overview
- Market Revenue
- Liver Cancer
- Market Overview
- Market Revenue
- Cervical Cancer
- Market Overview
- Market Revenue
- Others
- Market Overview
- Market Revenue
Chapter 8 Market Breakdown by Region
- Introduction
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
- Rest of the World
Chapter 9 Industry Structure
- Competitive Landscape
- Patent Analysis
- Pipeline Analysis
- Prostate Cancer
- Breast Cancer
- Cervical Cancer
- Liver Cancer
- Lung Cancer
- Stomach Cancer
- Colorectal Cancer
- Esophageal Cancer
Chapter 10 Current Situation
- Overview
- Factors Affecting Cancer Vaccines
- Increasing Prevalence of Cancer
- Aging Population
- Lifestyle Changes
- Approvals for Additional Indications
- Competition
- Increased Funding
- Manufacturers' Strategies
- Challenges in Cancer Vaccines
Chapter 11 Company Profiles
- Amgen Inc.
- Anixa Biosciences Inc.
- Dendreon Corp.
- Etherna
- F. Hoffmann-La Roche Ltd.
- Glaxosmithkline Plc
- Immunicum Ab
- Inovio Pharmaceuticals Inc.
- Merck & Co. Inc.
- Moderna Inc.
- OSE Immunotherapeutics
- Providence Therapeutics Holdings Inc.
- Ubivac
- Vaccinogen Inc.
Chapter 12 Other International Companies
- Adamis Pharmaceuticals Corp.
- Advaxis Inc.
- Alphavax Inc.
- Bellicum Pharmaceuticals Inc.
- Candel Therapeutics Inc.
- Celldex Therapeutics Inc.
- Curevac Ag
- Genexine Inc.
- Globeimmune Inc.
- Gradalis Inc.
- Immunovative Therapies Ltd.
- ISA Pharmaceuticals B.V.
- Oncovir Inc.
- Sotio A.S.
- Vaxon Biotech
Chapter 13 Appendix A: Acronyms
List of Tables
Summary Table A: Global Market for Cancer Vaccines, by Type, Through 2026
Summary Table B: Global Market for Cancer Vaccines, by Region, Through 2026
Table 1: History of Cancer and Its Management
Table 2: COVID-19 Reported Cases and Deaths, by Country
Table 3: Regulatory Approvals of Cancer Vaccines
Table 4: Product Recalls of Cancer Vaccines
Table 5: Significant Orphan Drug Designations Approved
Table 6: Global Market for Cancer Vaccines, by Type, Through 2026
Table 7: Global Market for Cancer Vaccines, by Application, Through 2026
Table 8: Global Market for Prostate Cancer Vaccines, by Region, Through 2026
Table 9: Global Market for Liver Cancer Vaccines, by Region, Through 2026
Table 10: Global Market for Cervical Cancer Vaccines, by Region, Through 2026
Table 11: Global Market for Other Cancer Vaccines, by Region, Through 2026
Table 12: Global Market for Cancer Vaccines, by Region, Through 2026
Table 13: North American Market for Cancer Vaccines, by Type, Through 2026
Table 14: North American Market for Cancer Vaccines, by Application, Through 2026
Table 15: North American Market for Cancer Vaccines, by Country, Through 2026
Table 16: European Market for Cancer Vaccines, by Type, Through 2026
Table 17: European Market for Cancer Vaccines, by Application, Through 2026
Table 18: European Market for Cancer Vaccines, by Country, Through 2026
Table 19: Asia-Pacific Market for Cancer Vaccines, by Type, Through 2026
Table 20: Asia-Pacific Market for Cancer Vaccines, by Application, Through 2026
Table 21: Asia-Pacific Market for Cancer Vaccines, by Country, Through 2026
Table 22: Rest of the World Market for Cancer Vaccines, by Type, Through 2026
Table 23: Rest of the World Market for Cancer Vaccines, by Application, Through 2026
Table 24: Leading Manufacturers of Cancer Vaccines, by Sales, 2020
Table 25: Patent Filed for Cancer Vaccines
Table 26: Significant Prostate Cancer Vaccines in Development
Table 27: Number of Clinical Trials on Prostate Cancer Vaccines
Table 28: Significant Breast Cancer Vaccines in Development
Table 29: Number of Clinical Trials on Breast Cancer Vaccines
Table 30: Significant Cervical Cancer Vaccines in Development
Table 31: Number of Clinical Trials on Cervical Cancer Vaccines
Table 32: Significant Liver Cancer Vaccines in Development
Table 33: Number of Clinical Trials on Liver Cancer Vaccines
Table 34: Significant Lung Cancer Vaccines in Development
Table 35: Number of Clinical Trials on Lung Cancer Vaccines
Table 36: Significant Stomach Cancer Vaccines in Development
Table 37: Number of Clinical Trials on Stomach Cancer Vaccines
Table 38: Significant Colorectal Cancer Vaccines in Development
Table 39: Number of Clinical Trials on Colorectal Cancer Vaccines
Table 40: Significant Esophageal Cancer Vaccines in Development
Table 41: Number of Clinical Trials on Esophageal Cancer Vaccines
Table 42: Abbreviations Used in This Report
List of Figures
Summary Figure A: Global Market Shares of Cancer Vaccines, by Application, 2020
Summary Figure B: Global Market for Cancer Vaccines, by Region, 2019–2026
Figure 1: Global Market Shares of Cancer Vaccines, by Type, 2020
Figure 2: Global Market for Therapeutic Vaccines, 2020–2026
Figure 3: Global Market for Therapeutic Vaccines, by Region, 2020–2026
Figure 4: Global Market for Prophylactic Vaccines, 2020–2026
Figure 5: Global Market for Prophylactic Vaccines, by Region, 2020–2026
Figure 6: Global Market Shares of Cancer Vaccines, by Application, 2020
Figure 7: Global Market for Prostate Cancer Vaccines, 2020–2026
Figure 8: Global Market for Prostate Cancer Vaccines, by Region, 2020–2026
Figure 9: Global Market for Liver Cancer Vaccines, 2020–2026
Figure 10: Global Market for Liver Cancer Vaccines, by Region, 2020–2026
Figure 11: Global Market for Cervical Cancer Vaccines, 2020–2026
Figure 12: Global Market for Cervical Cancer Vaccines, by Region, 2020–2026
Figure 13: Global Market for Other Cancer Vaccines, 2020–2026
Figure 14: Global Market for Other Cancer Vaccines, by Region, 2020–2026
Figure 15: Global Market for Cancer Vaccines, by Region, 2020–2026
Figure 16: North American Market Shares of Cancer Vaccines, by Type, 2020
Figure 17: North American Market Shares of Cancer Vaccines, by Application, 2020
Figure 18: North American Market Shares of Cancer Vaccines, by Country, 2020
Figure 19: U.S. Market for Cancer Vaccines, 2020–2026
Figure 20: Canadian Market for Cancer Vaccines, 2020–2026
Figure 21: European Market Shares of Cancer Vaccines, by Type, 2020
Figure 22: European Market Shares of Cancer Vaccines, by Application, 2020
Figure 23: European Market Shares for Cancer Vaccines, by Country, 2020
Figure 24: German Market for Cancer Vaccines, 2020–2026
Figure 25: U.K. Market for Cancer Vaccines, 2020–2026
Figure 26: French Market for Cancer Vaccines, 2020–2026
Figure 27: Italian Market for Cancer Vaccines, 2020–202
Figure 28: Spanish Market for Cancer Vaccines, 2020–2026
Figure 29: Rest of European Market for Cancer Vaccines, 2020–2026
Figure 30: Asia-Pacific Market Shares of Cancer Vaccines, by Type, 2020
Figure 31: Asia-Pacific Market Shares of Cancer Vaccines, by Application, 2020
Figure 32: Asia-Pacific Market for Cancer Vaccines, by Country, 2020
Figure 33: Chinese Market for Cancer Vaccines, 2020–2026
Figure 34: Indian Market for Cancer Vaccines, 2020–2026
Figure 35: Japanese Market for Cancer Vaccines, 2020–2026
Figure 36: Rest of Asia-Pacific Market for Cancer Vaccines, 2020–2026
Figure 37: Rest of the World Market Shares of Cancer Vaccines, by Type, 2020
Figure 38: Rest of the World Market Shares of Cancer Vaccines, by Application, 2020
Figure 39: Global Manufacturers Market Shares of Cancer Vaccines, 2020
Samples
LOADING...
Executive Summary
Cancer therapy remains a challenge despite advances in diagnostics and on-hand therapies. Available cancer therapies have side effects and are especially less effective in recurrent cancers. Over the past few years, the concept of recruiting the entire immune system to fight cancer has been at the forefront of cancer research. To develop efficacious cancer vaccines, researchers have explored an array of different approaches, such as peptide vaccines and dendritic cell vaccines. Some of the cancer vaccines showed tantalizing results, but real success is still awaited. The majority of vaccines developed and tested were unable to boost the body’s immune system to a point where these vaccination strategies could be effectively utilized to cure cancer; thus, only a few vaccines are presently in the market. Cancer vaccines can be broadly categorized into therapeutic vaccines and prophylactic vaccines. Therapeutic vaccines, as the name suggests, are intended to treat existing cancer, whereas prophylactic, or preventive, vaccines are used to prevent cancer from developing in healthy people.
In April 2010, the U.S. Food and Drug Administration (FDA) approved Provenge, a prostate cancer vaccine, making researchers optimistic about the success of therapeutic cancer vaccines. In the wake of highly unmet need, a number of pharmaceutical companies entered into the cancer vaccines market. Moreover, dwindling research and development (R&D) and an increasing number of patent expirations forced pharmaceutical manufacturers to enter into this lucrative market through collaborations and licensing agreements. Merck & Co., GlaxoSmithKline and Dendreon Corp. (now part of Valeant Pharmaceuticals International Inc.) are the three leading companies in the market.
Market Size and Evolution
Because the cancer vaccine market is in its infancy, there are a limited number of products in the market. Increasing incidence of cancer, unavailability of efficacious treatments and the necessity to reduce the global burden of cancer are major driving forces for the market. High manufacturing costs and competition from comparatively low-cost therapies are the two biggest hurdles in the way of success.
Companies Mentioned
- Adamis Pharmaceuticals Corp.
- Advaxis Inc.
- Alphavax Inc.
- Amgen Inc.
- Anixa Biosciences Inc.
- Bellicum Pharmaceuticals Inc.
- Candel Therapeutics Inc.
- Celldex Therapeutics Inc.
- Curevac Ag
- Dendreon Corp.
- Etherna
- F. Hoffmann-La Roche Ltd.
- Genexine Inc.
- Glaxosmithkline Plc
- Globeimmune Inc.
- Gradalis Inc.
- Immunicum Ab
- Immunovative Therapies Ltd.
- Inovio Pharmaceuticals Inc.
- ISA Pharmaceuticals B.V.
- Merck & Co. Inc.
- Moderna Inc.
- Oncovir Inc.
- OSE Immunotherapeutics
- Providence Therapeutics Holdings Inc.
- Sotio A.S.
- Ubivac
- Vaccinogen Inc.
- Vaxon Biotech
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 155 |
| Published | July 2021 |
| Forecast Period | 2021 - 2026 |
| Estimated Market Value ( USD | $ 8.1 Billion |
| Forecasted Market Value ( USD | $ 11.7 Billion |
| Compound Annual Growth Rate | 7.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 29 |
